题名 | Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production |
作者 | |
发表日期 | 2023-08-17 |
发表期刊 | Immunopharmacology and immunotoxicology 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Journal Article |
关键词 | FOXO1 IGF2BP3 JAK2/STAT3 signaling ROS Withaferin A hepatocellular carcinoma |
其他关键词 | FOXO1 ; PROLIFERATION ; CELLS |
摘要 | Objective: This study aimed to investigate the underlying molecular mechanisms of Withaferin A (WA) in hepatocellular carcinoma (HCC).Materials and Methods: The gene and protein expression were analyzed using RT-qPCR and western blot, respectively. The proliferation of HCC cells was evaluated by CCK-8 assays. The migrative ability of HCC cells was measured by transwell assays.Results: We revealed that WA suppressed the proliferation and migration of HCC cells and inhibited IGF2BP3 (insulin like growth factor 2 mRNA binding protein 3) expression. IGF2BP3 abundance reversed the reactive oxygen species (ROS) accumulation and suppression of HCC cell proliferation and migration induced by WA. Besides, IGF2BP3 suppressed ROS production to promote the growth and migration of HCC cells. Furthermore, we found that IGF2BP3 exerted its tumor-promotive and ROS-suppressive effect on HCC cells by regulating the expression of FOXO1 (forkhead box O1). In addition, IGF2BP3-stimulated activation of JAK2 (Janus kinase 2)/STAT3 (signal transducer and activator of transcription 3) phosphorylation effectively decreased the transcription of FOXO1. FOXO1 abundance decreased the phosphorylation of JAK2 and STAT3 by increasing ROS level, forming a feedback loop for the inhibition of JAK2/STAT3 signaling activated by IGF2BP3.Conclusions: WA-induced ROS inhibited HCC cell growth and migration through the inhibition of IGF2BP3 to deactivate JAK2/STAT3 signaling, resulting in increased FOXO1 expression to further stimulate ROS production and inhibit JAK2/STAT3 signaling |
资助项目 | Medical and Health Research Project of Zhejiang Province [2022KY353]; Young Talent Development Plan of Changzhou Health Commission [CZQM2020049]; Applied Basic Research of Changzhou Technology Bureau [CJ20220118] |
出版者 | TAYLOR & FRANCIS LTD |
ISSN | 0892-3973 |
EISSN | 1532-2513 |
卷号 | 46期号:1页码:40-48 |
DOI | 10.1080/08923973.2023.2247552 |
页数 | 9 |
WOS类目 | Immunology ; Pharmacology & Pharmacy ; Toxicology |
WOS研究方向 | Immunology ; Pharmacology & Pharmacy ; Toxicology |
WOS记录号 | WOS:001059564400001 |
收录类别 | PUBMED ; SCIE ; SCOPUS |
URL | 查看原文 |
PubMed ID | 37671837 |
SCOPUSEID | 2-s2.0-85169911861 |
通讯作者地址 | [Yang, Yu]Department of Hepatopancreatobiliary Surgery,The Third Affiliated Hospital of Soochow University,185 Juqian Street, Jiangsu,Changzhou,213000,China |
Scopus学科分类 | Immunology and Allergy;Immunology;Toxicology;Pharmacology |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/182773 |
专题 | 其他_附属第三医院(瑞安市人民医院) |
通讯作者 | Yang, Yu |
作者单位 | 1.Department of Hepatobiliary Surgery,The Third Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Department of Hepatopancreatobiliary Surgery,The Third Affiliated Hospital of Soochow University,Changzhou,China |
第一作者单位 | 其他_附属第三医院(瑞安市人民医院) |
第一作者的第一单位 | 其他_附属第三医院(瑞安市人民医院) |
推荐引用方式 GB/T 7714 | Li, Jinhai,Ge, Mengchen,Deng, Pengcheng,et al. Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production[J]. Immunopharmacology and immunotoxicology,2023,46(1):40-48. |
APA | Li, Jinhai, Ge, Mengchen, Deng, Pengcheng, Wu, Xinquan, Shi, Longqing, & Yang, Yu. (2023). Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production. Immunopharmacology and immunotoxicology, 46(1), 40-48. |
MLA | Li, Jinhai,et al."Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production".Immunopharmacology and immunotoxicology 46.1(2023):40-48. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论